SCHEMBL20914328

SCHEMBL20914328

COc1cccc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C5CC5)nn4c3=O)nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 2/20 0.36
▸ TNKS2 Q9H2K2 2/20 0.36
▸ PARP2 Q9UGN5 1/20 0.36
▸ F2RL3 Q96RI0 2/20 0.36
▸ PLAT P00750 3/20 0.35
▸ PDE4D Q08499 3/20 0.35
▸ HTR3A P46098 2/20 0.34
▸ KCNH2 Q12809 2/20 0.34
▸ CYP3A4 P08684 2/20 0.33
▸ CCR2 P41597 1/20 0.33
▸ ARF6 P62330 1/20 0.32
▸ DCTPP1 Q9H773 1/20 0.32
▸ CYP1A1 P04798 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP1B1 Q16678 1/20 0.32
▸ TOP2A P11388 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ MAPT P10636 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914016 0.88 TNKS (0.39) TNKSTNKS2PARP2F2RL3PLAT
SCHEMBL20931219 0.88 TNKS (0.40) TNKSTNKS2PARP2F2RL3PLAT
SCHEMBL20914415 0.87 TNKS (0.39) TNKSTNKS2PARP2F2RL3CYP3A4
SCHEMBL20914083 0.85 TNKS (0.38) TNKSTNKS2PARP2F2RL3CYP3A4
SCHEMBL20837241 0.85 PLAT (0.35) TNKSTNKS2PARP2F2RL3PLAT
SCHEMBL20914255 0.84 TNKS (0.37) TNKSTNKS2PARP2F2RL3HTR3A
SCHEMBL20914002 0.84 TNKS (0.37) TNKSTNKS2PARP2F2RL3CYP3A4
SCHEMBL20837249 0.84 TNKS (0.37) TNKSTNKS2PARP2F2RL3CYP3A4
SCHEMBL20819069 0.84 TNKS (0.37) TNKSTNKS2PARP2F2RL3CYP3A4
SCHEMBL20914212 0.84 TNKS (0.37) TNKSTNKS2PARP2F2RL3PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback